A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.

@article{ZelberSagi2006ADR,
  title={A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.},
  author={Shira Zelber-Sagi and Ada Kessler and Eli Brazowsky and Muriel Webb and Yoav Lurie and Moshe Santo and Moshe M Leshno and Laurence M. Blendis and Zamir Halpern and Ran Oren},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2006},
  volume={4 5},
  pages={639-44}
}
BACKGROUND & AIMS Few controlled studies have addressed the issue of effective medical treatment for nonalcoholic fatty liver disease (NAFLD). We herein assessed the effect of orlistat in patients with NAFLD. METHODS We performed a randomized, double-blind, placebo-controlled study on 52 patients with NAFLD diagnosed by ultrasound (US) and confirmed by liver biopsy (40 patients). The patients were randomized to receive either orlistat (120 mg 3 times daily for 6 months) or placebo. All… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Nonalcoholic fatty liver disease.

Revista de gastroenterologia de Mexico • 2005

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

Obesity reviews : an official journal of the International Association for the Study of Obesity • 2004

Pharmacotherapy of obesity: currently marketed and upcoming agents.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2002

Similar Papers

Loading similar papers…